)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AVROBIO
AVROBIO (AVRO) investor relations material
AVROBIO has been acquired
AVROBIO Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary7 Jul, 2025
Company overview and business model
Clinical-stage biotechnology company developing therapeutic proteins and antibodies targeting GPCRs, a historically challenging class for biologics.
Proprietary GEODe™ platform enables discovery of GPCR-targeted biologic medicines for diseases with significant unmet need.
Lead asset TX45 is in Phase 1b and Phase 2 trials for pulmonary hypertension in heart failure; early data show favorable safety and efficacy signals.
Second candidate, TX2100, targets Hereditary Hemorrhagic Telangiectasia, with IND-enabling studies underway and Phase 1 planned for late 2025 or early 2026.
Company recently completed a merger and operates as a smaller reporting company, allowing reduced disclosure obligations.
Financial performance and metrics
Net tangible book value as of March 31, 2025: $301.0 million, or $16.12 per share.
After a $100 million offering at $21.34/share, as adjusted net tangible book value would be $17.03 per share, with $397.7 million in net tangible book value.
Immediate dilution to new investors in the offering is estimated at $4.31 per share.
Use of proceeds and capital allocation
Net proceeds intended for continued clinical development of pipeline products, working capital, and general corporate purposes.
May also use proceeds for in-licensing, acquisitions, or investments in complementary businesses, though no current commitments exist.
Pending use, proceeds will be invested in investment-grade, interest-bearing instruments.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AVROBIO
- Annual meeting to vote on directors, auditor, executive pay, and governance matters.AVRO
Proxy Filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AVROProxy Filing
- Biotech innovator registers resale of 2.97M shares; early-stage, pre-revenue, post-merger.AVRORegistration Filing
- Biotech with novel GPCR biologics, $185M raised, advancing early-stage PH-HFpEF and HHT programs.AVRORegistration Filing
- Q3 net loss was $17.7M; $159.1M cash funds operations into mid-2027 as clinical trials advance.AVROQ3 2024
AVROBIO
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AVROBIO, Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies using a lentiviral-based platform. These therapies are designed to treat rare diseases with a single dose, and involve modifying hematopoietic stem cells extracted from patients. AVROBIO focuses on a range of genetic disorders, employing its proprietary plato® platform to optimize these therapies. Notable diseases targeted by AVROBIO's gene therapies include Gaucher disease, Pompe disease, cystinosis, and Hunter syndrome, with several treatments in various stages of clinical trials. The company was established in 2015 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ.